Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS
ANAkinra in Severe Juvenile Idiopathic Arthritis of Systemic Onset (ANAJIS)
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
A PHASE2/PHASE3 clinical study on Systemic-Onset Juvenile Idiopathic Arthritis, this trial is completed. The trial is conducted by Institut National de la Santé Et de la Recherche Médicale, France and has accumulated 7 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2025 — Feb 2026 [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
First recorded
May 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institut National de la Santé Et de la Recherche Médicale, France
For direct contact, visit the study record on ClinicalTrials.gov .